Plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) predict risk of sudden cardiac death (SCD) in patients with known cardiac disease, but currently there are no data for SCD risk prediction in populations unselected on the basis of cardiac disease. In this nested case-control analysis within the 121 700person Nurses' Health Study, 99 cases of definite or probable SCD were identified and matched to 294 controls on the basis of age, smoking, and prior cardiovascular disease. Baseline plasma NT-proBNP levels, but not C-reactive protein or lipid levels, were significantly associated with SCD using a multivariable model adjusted for coronary heart disease risk factors and other biomarkers. After multivariable adjustment, each 1-SD increment in log NT-proBNP was associated with an Ϸ50% increase in the risk of SCD, and levels above the prespecified cut point of 389 pg/mL were associated with a 5-fold increased risk of SCD. These findings offer potential insights into the pathophysiology underlying SCD in women. Specifically, they point to increased myocardial wall stress, along with associated left ventricular dilatation, hypertrophy, and/or fibrosis, as potential mediators of electrical instability leading to SCD in women. The lack of association of other well-established coronary heart disease risk factors (including high-sensitivity C-reactive protein) suggests that mechanicalelectrical disturbances might play a greater role than undetected atherosclerosis in SCD risk among women. If confirmed in larger studies, marked elevations in NT-proBNP levels might also be useful in identifying women at higher risk for SCD many years before the fatal event.
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
Patients with acute coronary syndromes continue to have recurrent ischemic events despite revascularization and current antiplatelet therapy. Several novel oral anticoagulants that may reduce recurrent ischemic events are being developed but come with an increased risk of bleeding. Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) is the first phase 2 trial exploring several doses of the oral factor Xa inhibitor, apixaban, in patients, with a recent acute coronary syndrome who received, in many cases, both aspirin and clopidogrel. With the addition of apixaban, there was an increase in bleeding but also promising reductions in clinically important ischemic events, including cardiovascular death, myocardial infarction, stroke, and recurrent ischemia requiring hospitalization or revascularization. The results of APPRAISE set the stage for adequately powered phase 3 trials of apixaban in patients with recent acute coronary syndromes, which, depending on their results, may establish oral anticoagulation as a new standard approach for preventing recurrent ischemic events in patients with acute coronary syndromes. See p 2877.
Effects of Prior Intensive Insulin Therapy on Cardiac Autonomic Nervous System Function in Type 1 Diabetes Mellitus: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC)
We present prospective findings of cardiovascular autonomic neuropathy (CAN) in patients with type 1 diabetes mellitus enrolled in the Diabetes Control and Complications Trial (DCCT) and followed up annually through the Epidemiology of Diabetes Interventions and Complications (EDIC) for an additional 13 to 14 years after the DCCT closeout. CAN is associated with a high risk of cardiac arrhythmias and sudden death, possibly related to silent myocardial ischemia. Our study provides a comprehensive CAN assessment over 25 years in a well-characterized cohort of patients with type 1 diabetes mellitus. The prevalence and incidence of CAN, as assessed by heart rate variability, increased substantially from DCCT closeout to EDIC year 13/14 despite the young age of the cohort, a very low prevalence of CAN at DCCT closeout, and good glycemic control. Even after adjustment for the level or presence of CAN at DCCT closeout, there were persistent beneficial effects of prior intensive versus conventional therapy after 13 to 14 years of follow-up in EDIC. Treatment group differences in the mean level of hemoglobin A 1c during DCCT and EDIC explained virtually all of the beneficial effects of intensive versus conventional therapy on risk of incident CAN. These findings support the recommendation that intensive treatment of type 1 diabetes mellitus be initiated as early as possible to provide durable protection from the development and progression of diabetic complications. See p 2886.
Tadalafil Therapy for Pulmonary Arterial Hypertension
There is no cure for pulmonary arterial hypertension, a devastating, progressive disease with increasingly debilitating symptoms. Currently approved treatment options include prostanoids, endothelin receptor antagonists, and a phosphodiesterase type-5 inhibitor. These therapies improve symptoms, exercise capacity, hemodynamics, and clinical outcome but are limited by either parenteral or inhaled delivery systems, the need for laboratory monitoring, or frequent dosing schedules. In addition, the majority of pivotal trials have shown the efficacy-to-safety balance of the approved medications when administered as monotherapy, and less information is available on the effects of these drugs when combined with background therapy with other approved compounds. The results of the Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) study provide evidence for the efficacy of the orally active phosphodiesterase type-5 inhibitor tadalafil at a dose of 40 mg once daily. The effects on exercise capacity and hemodynamics are comparable to those of the other drugs approved for pulmonary arterial hypertension. Furthermore, tadalafil 40 mg is able to improve time to clinical worsening, most adverse events were mild to moderate in severity, and there were no clinically significant changes in laboratory variables measured. Therefore, the favorable efficacy-to-safety profile of tadalafil 40 mg once daily offers a clinically meaningful addition to the currently approved treatment options. Approximately 50% of the patients enrolled in the PHIRST study were on background therapy with the endothelin receptor antagonist bosentan; in this subgroup as well, the favorable effects of tadalafil 40 mg were confirmed, although by a lesser extent. These data may support the use of combination therapy in pulmonary arterial hypertension. See p 2894.
Regulatory T Cells Ameliorate Angiotensin II-Induced Cardiac Damage
Regulatory T (Treg) cells keep the immune system under control. When they are absent, fulminant autoimmunity may occur. Treg cells have been implicated in cardiovascular diseases, including atherosclerosis and diabetes mellitus. A therapeutic potential for Treg cells has been suggested in combating allograft rejection and autoimmune diseases. In earlier studies, we were impressed by the participation of immune responses in angiotensin II (Ang II)-mediated target organ damage. Innate and adaptive cellular and even antibody responses can be observed. Here, we test the notion that Treg cells would control inflammation in a mouse model involving sustained Ang II infusion. Control mice develop hypertension, cardiac hypertrophy, and easily evoked ventricular arrhythmias after catheter stimulation. The hearts exhibit immune cell infiltration, tumor necrosis factor-␣ expression, and fibrosis. We injected Treg cells obtained from spleens and lymph nodes of donor mice into mice that then received Ang II. Telemetric blood pressure measurements were the same. However, Treg-treated mice developed less cardiac hypertrophy, less tumor necrosis factor-␣ expression, and less immune cell infiltration and resisted stimulated arrhythmia. We found that Ang II did not directly influence Treg cells. However, Treg treatment maintained other T-cell populations closer to the proportion observed in control mice compared with mice given Ang II but no Treg cells. The importance of our findings is mechanistic. Our results underscore earlier observations on T lymphocytes, other immune cells, and their regulators in blood pressure responses and target organ damage after Ang II treatment. They suggest additional avenues of research relative to Ang II-related target organ damage and immunity. See p 2904.
Youth With Obesity and Obesity-Related Type 2 Diabetes Mellitus Demonstrate Abnormalities in Carotid Structure and Function
Adults with obesity or type 2 diabetes mellitus (T2DM) are at higher risk for stroke and myocardial infarction. Many of these high-risk individuals demonstrate evidence of target organ damage in the carotid arteries (increased carotid intima-media thickness and carotid stiffness) well before the adverse cardiovascular outcomes occur. Whether similar changes in the carotid arteries occur in youth with obesity or T2DM is not known. Therefore, we compared carotid intima-media thickness and carotid stiffness in high-risk youth with lean controls. We found that youth with T2DM had significantly greater carotid intima-media thickness than lean subjects for all carotid segments (common, bulb, and internal), and their carotid intima-media thickness was thicker than in obese participants for the common carotid artery and bulb (all PՅ0.05). Obese and T2DM groups had stiffer carotid arteries with higher Young elastic modulus and beta stiffness index than the lean group. We conclude that youth with T2DM demonstrate significant abnormalities in carotid structure and function, and, in obese youth, changes are present well before progression to overt T2DM. The abnormalities are only partially explained by traditional cardiovascular risk factors such as age and blood pressure because the presence of obesity or diabetes mellitus contributed independently to carotid structure and function. The increasing prevalence of obesity across the globe may lead to a parallel increase in cardiovascular diseases. Therefore, pediatric healthcare practitioners should continue to screen for abnormalities in cardiovascular risk factors, especially in children with elevated body mass index or T2DM. Comprehensive lifestyle interventions to reduce obesity must be applied now to prevent a projected decline in life expectancy for our youth. See p 2913.
Standardized Low-Molecular-Weight Heparin Bridging Regimen in Outpatients on Oral Anticoagulants Undergoing Invasive Procedure or Surgery: An Inception Cohort Management Study
The management of patients on oral anticoagulant therapy that may require temporary interruption because of planned surgery or procedure is a common yet challenging clinical scenario. In most cases, perioperative bleeding and thromboembolism can be avoided by performing adequate "bridging" with low-molecular-weight heparin. Although the validity of perioperative bridging is generally accepted, a single standardized bridging regimen is still lacking, mainly because the published studies are characterized by significant variations in patient population, study design, bridging regimens, and duration of follow-up. In this large-scale multicenter study, we assessed the safety and efficacy of a generalizable bridging regimen. The use of subtherapeutic doses of low-molecular-weight heparin in high-thromboembolic-risk patients was associated with a very low bleeding incidence on the one hand and a very low thromboembolic incidence on the other. The same effectiveness and safety were observed for prophylactic doses in low-to intermediatethromboembolic-risk patients. The bleeding risk of the intervention, which because of the lack of general definitions might under many circumstances be a confounder to bridging, was not related to the periprocedural bleeding. This protocol provides anticoagulation centers with a general framework on how to perform bridging in most clinical scenarios. However, as in most circumstances in medicine, each case should be considered individually; in particular, patients with mechanical heart valves might benefit from consultation among the anticoagulation physician, the cardiologist, and the surgeon. The results of this study show that this regimen might be a practical bridging guide in everyday clinical practice. See p 2920.
Vascular Regeneration by Local Growth Factor Release Is Self-Limited by Microvascular Clearance
Proangiogenic growth factors have long been considered for regenerating ischemic tissues. Yet, sustained clinical benefit has not followed promising preclinical findings even with advances in local delivery technology. Quantitative and animal models suggest that the limited late efficacy of local delivery of angiogenic factors stems partly from the very early success at inducing vessel growth. Fibroblast growth factor released from a polymeric implant penetrates ischemic rabbit myocardium in vivo for the first 2 days of local delivery and indeed induces neovascularization. But, as new vessels are formed, drug is cleared rapidly, and the induced vessel mass regresses. As each wave of new vessels appears in response to the angiogenic factor pools, the factors are cleared, and the angiogenic signal abates as a receding wave that implodes back toward the growth factor source. Despite a constantly eluting source of fibroblast growth factor, the front of new vessels continues to fall back. Eight days after release initiation, neovascularization remains but only as a regressed zone immediately around the delivery device. By day 30, there is only a superficial layer of vessels around the release device. This interdependence of pharmacokinetics and pharmacodynamics may explain the difficulty of realizing sustained clinical angiogenesis with local release and suggests that efficacy depends on device placement and drug transendothelial permeability. The quantitative framework presented here may help guide rational selection of specific angiogenic compounds on the basis of a favorable physicochemical profile and drug delivery strategies that take advantage of the tight regulation between growth factor pharmacokinetics and angiogenic pharmacodynamics. See p 2928.
